Efficacy and safety of 4-weekly cabazitaxel for castration-resistant prostate cancer: a multi-institutional study
Conclusions3-weekly and 4-weekly regimens of cabazitaxel showed similar efficacy and safety profiles in a real-world clinical setting. These data suggest that a 4-weekly regimen may be acceptable for selected patients.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Drugs & Pharmacology | Japan Health | Prostate Cancer | Study